Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Therapy for High-Risk Pediatric Solid Tumors
NCT02446431Phase 1Recruiting
- Sponsor
- MemorialCare Miller Children's & Women's Hospital Long Beach
- Start
- Jul 2014
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab, cyclophosphamide, valproic acid and temsirolimus in solid tumor, rhabdomyosarcoma (RMS), osteosarcoma (OS) and 2 more, sponsored by MemorialCare Miller Children's & Women's Hospital Long Beach. Primary endpoints: 5 year Event Free Survival and Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 5 years. Started Jul 2014; status: recruiting.
02
Drugs
bevacizumabcyclophosphamidevalproic acidtemsirolimus
03
Conditions
solid tumorrhabdomyosarcoma (RMS)osteosarcoma (OS)Ewing sarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02446431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446431.